Evidence map›Paper›PMID 38965810›Full record

Observational studyUnited European gastroenterology journal2024

Initiation of vedolizumab did not provoke new-onset spondylarthritis in patients with inflammatory bowel disease: A prospective 24-week study with imaging assessments.

Sherry Rohekar, Tristan Boyd, Robert G Lambert, Melanie Beaton, Nilesh Chande, Jamie Gregor, Heather Lennox, Keith Mcintosh, Terry Ponich, Adam Rahman and 4 more

Abstract readObservational Study
PubMed Full text at PMC Publisher
In one paragraph

Observational study in United European gastroenterology journal, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Understanding the therapeutic toolkit for inflammatory bowel disease.Nature reviews. Gastroenterology & hepatology · 2025
    Review
  3. Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Sherry RohekarDepartment of Medicine, Division of Rheumatology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Tristan BoydDepartment of Medicine, Division of Rheumatology, Schulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Robert G LambertDepartment of Radiology and Diagnostic Imaging, University of Alberta, Edmonton, Alberta, Canada.
Melanie BeatonDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Nilesh ChandeSouthwestern Ontario Inflammatory Bowel Disease Clinic, London, Ontario, Canada.
Jamie GregorDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Heather LennoxLondon Health Sciences Centre, London, Ontario, Canada.
Keith McintoshDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Terry PonichDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Adam RahmanDepartment of Medicine, Division of Gastroenterology, Western University, London, Ontario, Canada.
Trimadhu SharmaLawson Health Research Institute, London, Ontario, Canada.ORCID 0009-0001-8444-1967
Michael SeyLawson Health Research Institute, London, Ontario, Canada.
Maria TauqirSchulich School of Medicine & Dentistry, Western University, London, Ontario, Canada.
Vipul JairathLawson Health Research Institute, London, Ontario, Canada.ORCID 0000-0002-1092-0033

Funding

SPARCC Research Pilot Project Program
6 · The paper itself

Abstract

backgroundA temporal relationship between vedolizumab and new-onset spondyloarthritis (SpA) has been suggested.

aimsWe evaluated the relationship between vedolizumab initiation and development of new-onset SpA in patients with inflammatory bowel disease (IBD) through serial clinical evaluation and magnetic resonance imaging (MRI).

methodsA single-centre prospective observational study of 24 patients with IBD. Patients were eligible if they had active ulcerative colitis or Crohn's disease (CD), were initiating vedolizumab, had no prior history of arthritis or SpA and were suitable for serial MRI. A rheumatologist performed clinical evaluation prior to the first dose and 8 and 24 weeks. Axial MRI was evaluated by a blinded central reader and performed at baseline 8 and 24 weeks.

resultsNine tumor necrosis factor (TNF) inhibitor-naïve patients (4 male; mean age 53.2 years; 6 UC; 3 CD) and eight TNF inhibitor-experienced patients (7 male; mean age 48 years; 3 UC; 5 CD) completed all assessments. No patients developed new features of axial arthritis or features of peripheral SpA (inflammatory oligoarthritis, enthesitis, dactylitis, or psoriasis (nail, body, or scalp)). Both groups demonstrated a good intestinal response.

conclusionVedolizumab initiation did not induce new features of axial or peripheral SpA after 24 weeks of treatment in TNF inhibitor-experienced or TNF inhibitor-naive patients with IBD.

Indexed as

Antibodies, Monoclonal, HumanizedMagnetic Resonance ImagingSpondylarthritisAdultCrohn DiseaseFemaleGastrointestinal AgentsHumansInflammatory Bowel DiseasesMaleMiddle AgedProspective StudiesAntibodies, Monoclonal, HumanizedGastrointestinal AgentsvedolizumabCrohn's diseaseinflammatory bowel diseasespondyloarthritisulcerative colitis (UC)vedolizumab

Identifiers

PMID38965810
PMCPMC11497674

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.